Testing for the presence of BRAF V600E mutation may be relevant in clinical neuropathology practice for the following reason: BRAF mutations affect some brain tumors (both primary and secondary) [3, 6] and small molecule drugs specifically inhibiting the mutated BRAF protein have been developed. Here, BRAF is linked to brain neoplasm.